Replies to post #336400 on Innovation Pharmaceuticals Inc (IPIX)

[steelyeye]

If so, it could tie to this from the 10Q:

We anticipate that future budget expenditures will be approximately $10.3 million for the fiscal year ending June 30, 2021, including approximately $8.3 million for clinical activities, supportive research, and drug product. Alternatively, if we decide to pursue a more aggressive plan with our clinical trials, we will require additional sources of capital during the fiscal year 2021 to meet our working capital requirements for our planned clinical trials. Potential sources for capital include grant funding for COVID-19 research and equity financings. There can be no assurances that we will be successful in receiving any grant funding for our programs.

Leo sees the big picture value of Brilacidin and wants to start pushing it hard on a number of fronts.

Just one more possibility for the recent raise..